The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...

WASHINGTON - The Food and Drug Administration has approved Exdensur as an add-on maintenance treatment for patients aged 12 ...

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist (LAMA) or a Leukotriene Receptor Antagonist (LTRA) on top of a moderate-dose ...

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%. The findings, published today in ...

Please provide your email address to receive an email when new articles are posted on . A 50% or greater reduction in exacerbation rate was one of the four criteria for response. Criteria also ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

* Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma - ...

A new study published in Respiratory Medicine offers hope for a long-term treatment of asthma by directly targeting the structural changes that occur in the airway and lungs. Unlike current drugs that ...